Document Detail

AMSA--a promising new agent in refractory acute leukemia.
MedLine Citation:
PMID:  7046928     Owner:  NLM     Status:  MEDLINE    
Forty-five patients with various forms of acute leukemia refractory to usual methods of treatment were treated with AMSA at doses of 100-200 mg/m2 iv daily for 5-7 days, for total doses of 500-1000 mg/m2/course. Among 41 evaluable patients, six (15%) achieved complete remissions, including two of 19 patients with typical acute nonlymphocytic leukemia, none of four with atypical acute nonlymphocytic leukemia, two of nine with chronic granulocytic leukemia in blast crisis, two of eight with acute lymphoblastic leukemia, and none of one with acute undifferentiated leukemia. Durations of complete remissions were 6, 7, 8, 12, 13, and 14 weeks. Four of the patients who died with infection during marrow hypoplasia 2-5 weeks after receiving AMSA had no evidence of leukemia on premortem bone marrow aspirates or postmortem examination. The primary toxic effects of AMSA were severe myelosuppression, stomatitis, and alopecia. One incident of life-threatening liver failure occurred. AMSA appears to be a promising agent for use in heavily pretreated patients with acute leukemia and chronic granulocytic leukemia in blast crisis.
H J Lawrence; C A Ries; R D Reynolds; J P Lewis; M M Koretz; F M Torti
Related Documents :
103308 - Preleukemic syndromes.
19782398 - P15ink4b methylation correlates with thrombocytopenia, blast percentage, and survival i...
1850308 - Clinical significance of soluble cd30 antigen in the sera of patients with untreated ho...
10997968 - Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes.
17064768 - Clinical response of myelodysplastic syndromes patients to treatment with coenzyme q10.
1138328 - The incidence of lactose malabsorption in ulcerative colitis.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer treatment reports     Volume:  66     ISSN:  0361-5960     ISO Abbreviation:  Cancer Treat Rep     Publication Date:  1982 Jul 
Date Detail:
Created Date:  1982-09-10     Completed Date:  1982-09-10     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7607107     Medline TA:  Cancer Treat Rep     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1475-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Aminoacridines / therapeutic use*
Antineoplastic Agents / therapeutic use*
Clinical Trials as Topic
Follow-Up Studies
Leukemia / drug therapy*
Leukemia, Myeloid, Acute / drug therapy
Middle Aged
Grant Support
Reg. No./Substance:
0/Aminoacridines; 0/Antineoplastic Agents; 51264-14-3/Amsacrine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tardive dyskinesia: pharmacology and clinical implications.
Next Document:  Clinical evaluation of succinylated Acinetobacter glutaminase-asparaginase in adult leukemia.